| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $111,159,936 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK099160 | Molecular dissection of the ciliary gate | 003 | 11 | NIH | 5/9/2025 | $41,762 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK099160 | Molecular dissection of the ciliary gate | 002 | 11 | NIH | 12/11/2024 | $375,861 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076636 | Advancing MR elastography to map mechanical signatures of key AD/ADRD processes | 000 | 3 | NIH | 11/28/2024 | $397,775 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 002 | 5 | NIH | 6/4/2025 | $62,740 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 000 | 5 | NIH | 1/3/2025 | $564,664 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB033008 | Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | 001 | 3 | NIH | 5/19/2025 | $61,981 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB033008 | Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | 000 | 3 | NIH | 12/5/2024 | $557,828 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 002 | 12 | NIH | 6/9/2025 | $40,350 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 001 | 12 | NIH | 2/13/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 000 | 12 | NIH | 1/13/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI178147 | Role of the CX3CL1-CX3CR1 signaling axis in IPMN | 000 | 2 | NIH | 12/18/2024 | $195,698 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM144351 | Methods for microbiome compositional data | 000 | 4 | NIH | 12/20/2024 | $295,083 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK059597 | Investigation of common disease mechanisms in nonsyndromic and syndromic PKD | 000 | 24 | NIH | 12/12/2024 | $529,467 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG086136 | Ameliorating Respiratory Neuromotor Dysfunctions in Aging and Alzheimer's Disease | 000 | 2 | NIH | 5/27/2025 | $605,879 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 001 | 3 | NIH | 5/30/2025 | $36,372 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 000 | 3 | NIH | 11/25/2024 | $327,341 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P50HD115283 | COllaboration for EQuity in Uterine Leiomyomas | 001 | 2 | NIH | 5/21/2025 | $1,516,960 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 000 | 2 | NIH | 3/20/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 001 | 10 | NIH | 6/10/2025 | $63,472 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 000 | 10 | NIH | 3/18/2025 | $714,049 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03OD039975 | Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts | 000 | 1 | NIH | 6/10/2025 | $1 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03OD039975 | Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts | 000 | 1 | NIH | 6/10/2025 | $320,799 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 001 | 4 | NIH | 6/17/2025 | $26,076 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 4 | NIH | 3/6/2025 | $293,355 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 001 | 2 | NIH | 5/22/2025 | $18,863 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 2 | NIH | 3/20/2025 | $169,773 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 000 | 11 | NIH | 3/14/2025 | $4,779,823 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 001 | 4 | NIH | 6/10/2025 | $41,397 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 000 | 4 | NIH | 2/28/2025 | $372,578 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 001 | 4 | NIH | 6/25/2025 | $62,245 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 4 | NIH | 3/17/2025 | $560,204 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 2 | NIH | 3/5/2025 | $530,118 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 002 | 5 | NIH | 4/15/2025 | -$11,002 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 000 | 5 | NIH | 2/18/2025 | $146,896 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036987 | AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma | 000 | 1 | NIH | 3/19/2025 | $546,874 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 001 | 3 | NIH | 5/22/2025 | $67,152 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 3 | NIH | 3/19/2025 | $604,359 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 000 | 1 | NIH | 2/24/2025 | $726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 001 | 1 | NIH | 4/3/2025 | -$726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 001 | 1 | NIH | 4/3/2025 | $726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 001 | 8 | NIH | 4/21/2025 | $64,338 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 000 | 8 | NIH | 3/19/2025 | $579,047 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 001 | 3 | NIH | 5/29/2025 | $52,545 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 000 | 3 | NIH | 3/3/2025 | $472,910 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 001 | 4 | NIH | 6/17/2025 | $38,059 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 000 | 4 | NIH | 3/10/2025 | $428,154 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K08DK127064 | Regulation of portal hypertension through neutrophil-platelet interactions in liver sinusoids | 002 | 5 | NIH | 4/23/2025 | $155,520 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL142068 | T Cell Immunity in Giant Cell Arteritis | 001 | 6 | NIH | 5/3/2025 | $581,040 |
|
